Genmab A/S Share Price Nasdaq
Stocks
GMAB
US3723032062
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq
21:00:00 23/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 34.75 USD | -1.33% |
|
+1.02% | +12.82% |
| 06:07am | Hansa Biopharma brings in two new board members | FW |
| 05:55am | Nordic stocks in North America, Astra Zeneca fell 1.2% | FW |
| Market Cap | 137B 20.87B 18.32B 17.22B 15.74B 29.42B 1,999B 29.63B 207B 80.18B 1,019B 78.37B 76.65B 3,305B | P/E 2026 * |
28.6x | P/E 2027 * | 20.6x |
|---|---|---|---|---|---|
| Enterprise Value | 156B 23.79B 20.88B 19.63B 17.95B 33.53B 2,279B 33.78B 236B 91.4B 1,162B 89.34B 87.38B 3,767B | EV / Sales 2026 * |
5.38x | EV / Sales 2027 * | 4.4x |
| Free-Float |
94.3% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| GMAB | Delayed | |
CBOE
| GMAB | Real-time | |
|
Börse Stuttgart
| GE91 | Delayed | |
|
Tradegate
| GE91 | Real-time | |
|
Deutsche Boerse AG
| GE91 | Delayed | |
|
Boerse Muenchen
| GE91 | Real-time |
Last Transcript: Genmab A/S
| 1 day | -1.33% | ||
| 1 week | +1.02% | ||
| Current month | +4.79% | ||
| 1 month | +3.89% | ||
| 3 months | +33.96% | ||
| 6 months | +35.32% | ||
| Current year | +12.82% |
| 1 week | 34.36 |  | 35.66 |
| 1 month | 32.21 | | 35.66 |
| Current year | 23.62 | | 35.66 |
| 1 year | 23.62 | | 35.66 |
| 3 years | 17.24 | | 36.71 |
| 5 years | 17.24 | | 47.5 |
| 10 years | 12.1 | | 49.07 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 31/05/2010 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 29/02/2020 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 15/08/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 31/10/2003 | |
| Director/Board Member | 58 | 31/12/2014 | |
| Director/Board Member | 75 | 31/12/2014 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.33% | +1.02% | - | - | 20.87B | |
| +0.06% | +6.49% | +60.29% | +111.13% | 74.18B | |
| -0.10% | -3.80% | +34.24% | +74.98% | 59.55B | |
| -2.05% | -3.46% | -18.60% | +352.20% | 25.84B | |
| -2.39% | +2.74% | +0.19% | -5.91% | 24.73B | |
| -0.72% | +1.34% | +21.77% | -9.80% | 20.87B | |
| +1.29% | -2.49% | +152.11% | +333.06% | 15.32B | |
| -2.44% | -0.09% | +42.50% | +164.11% | 14.06B | |
| -3.91% | -4.91% | -14.10% | +779.68% | 13.12B | |
| -1.12% | -3.04% | +15.72% | +234.56% | 11.85B | |
| Average | -1.27% | -0.40% | +32.68% | +226.00% | 28.84B | |
| Weighted average by Cap. | -0.84% | +0.70% | +36.29% | +161.37% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 28.99B 4.42B 3.88B 3.65B 3.33B 6.23B 423B 6.27B 43.78B 16.97B 216B 16.59B 16.23B 700B | 33.65B 5.13B 4.5B 4.23B 3.87B 7.23B 491B 7.28B 50.81B 19.7B 250B 19.25B 18.83B 812B |
| Net income | 4.97B 758M 665M 625M 572M 1.07B 72.59B 1.08B 7.51B 2.91B 37.01B 2.85B 2.78B 120B | 7.09B 1.08B 949M 892M 815M 1.52B 104B 1.54B 10.71B 4.15B 52.8B 4.06B 3.97B 171B |
| Net Debt | 19.17B 2.92B 2.56B 2.41B 2.2B 4.12B 280B 4.15B 28.95B 11.22B 143B 10.97B 10.73B 463B | 11.04B 1.68B 1.48B 1.39B 1.27B 2.37B 161B 2.39B 16.66B 6.46B 82.12B 6.31B 6.18B 266B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/09/26 | US$34.75 | -1.33% | 2,509,746 |
| 22/09/26 | US$35.22 | +1.53% | 2,297,611 |
| 21/09/26 | US$34.69 | -0.14% | 1,577,461 |
| 18/09/26 | US$34.74 | +0.59% | 2,711,562 |
| 17/09/26 | US$34.54 | +0.39% | 2,703,043 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
Select your edition
All financial news and data tailored to specific country editions
